Iovance Biotherapeutics, Inc. IOVA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $196.51M+20.5% | $163.08M+3.1% | $158.13M+19.4% | $132.47M-22.8% | $171.67M+48.4% | ||
| $116.94M-12.7% | $133.9M-6.1% | $142.67M-15.4% | $168.71M-10.3% | $188.05M-9.6% | ||
| $5.99M+0.2% | $5.98M+0.3% | $5.97M+0.4% | $5.94M+963% | $559K-91.2% | ||
| $290.91M+3.9% | $280.09M+4.9% | $266.98M+4.3% | $255.98M+12.4% | $227.65M+45.0% | ||
| $211.6M-3.3% | $218.77M+0.1% | $218.61M+6.4% | $205.48M+12.0% | $183.5M+35.4% | ||
| $12.93M+11.6% | $11.58M+18.0% | $9.82M-15.0% | $11.55M-27.4% | $15.89M+28.4% | ||
| $466.5M+5.4% | $442.69M+3.2% | $429.09M+1.6% | $422.5M-17.6% | $512.65M+12.2% | ||
| $131.39M+0.2% | $131.11M+3.5% | $126.65M+3.4% | $122.47M+9.8% | $111.58M+2.3% | ||
| $44.38M-3.3% | $45.9M-5.9% | $48.76M-2.4% | $49.95M-1.9% | $50.9M-7.8% | ||
| $269.1M-3.7% | $279.32M-2.1% | $285.21M-3.7% | $296.25M+3.8% | $285.36M+1.0% | ||
| $128.81M-1.0% | $130.15M-0.4% | $130.64M-0.4% | $131.19M+2.2% | $128.39M-1.0% | ||
| $8.29M+1.5% | $8.17M-11.9% | $9.27M-10.1% | $10.32M+2,322% | $426K+15.4% | ||
| $925.67M+1.4% | $913.17M+0.9% | $904.95M-0.3% | $907.44M-6.1% | $966.74M+6.2% | ||
| $37.45M+69.0% | $22.16M-29.1% | $31.24M-2.4% | $32M+12.3% | $28.49M+3.6% | ||
| $88.07M-20.8% | $111.16M+27.4% | $87.27M-2.0% | $89.08M+5.2% | $84.71M+3.4% | ||
| $2.9M-28.3% | $4.04M-35.6% | $6.28M-11.2% | $7.07M-16.8% | $8.5M-34.1% | ||
| $129.42M-6.5% | $138.36M+10.0% | $125.79M-2.6% | $129.16M+5.3% | $122.69M+0.3% | ||
| $43.88M-1.2% | $44.4M-1.8% | $45.21M+0.3% | $45.1M+2.0% | $44.22M-0.3% | ||
| $46.78M-3.4% | $48.44M-5.9% | $51.49M-1.3% | $52.17M-1.0% | $52.72M-7.9% | ||
| $74.49M-2.3% | $76.23M-0.8% | $76.88M-3.7% | $79.79M+4.7% | $76.18M-1.9% | ||
| $203.91M-5.0% | $214.59M+5.9% | $202.66M-3.0% | $208.95M+5.1% | $198.88M-0.6% | ||
| —— | —— | —— | —— | —— | ||
| $18K+5.9% | $17K+6.3% | $16K+14.3% | $14K0.0% | $14K+7.7% | ||
| $3.56B+3.1% | $3.46B+2.0% | $3.39B+3.0% | $3.29B+0.8% | $3.26B+5.4% | ||
| -$2.85B-2.8% | -$2.78B-2.7% | -$2.7B-3.5% | -$2.61B-4.5% | -$2.5B-4.9% | ||
| $12.65M-23.1% | $16.44M+2.1% | $16.1M-22.8% | $20.86M+231% | $6.29M+702% | ||
| $721.75M+3.3% | $698.58M-0.5% | $702.29M+0.5% | $698.49M-9.0% | $767.87M+8.1% | ||
| $925.67M+1.4% | $913.17M+0.9% | $904.95M-0.3% | $907.44M-6.1% | $966.74M+6.2% | ||
| $8.29M+1.5% | $8.17M-11.9% | $9.27M-10.1% | $10.32M+2,322% | $426K+15.4% | ||
| $44.38M-3.3% | $45.9M-5.9% | $48.76M-2.4% | $49.95M-1.9% | $50.9M-7.8% | ||
| $269.1M-3.7% | $279.32M-2.1% | $285.21M-3.7% | $296.25M+3.8% | $285.36M+1.0% | ||
| $44.38M-3.3% | $45.9M-5.9% | $48.76M-2.4% | $49.95M-1.9% | $50.9M-7.8% | ||
| $8.29M+1.5% | $8.17M-11.9% | $9.27M-10.1% | $10.32M+2,322% | $426K+15.4% | ||
| $116.94M-12.7% | $133.9M-6.1% | $142.67M-15.4% | $168.71M-10.3% | $188.05M-9.6% | ||
| $44.38M-3.3% | $45.9M-5.9% | $48.76M-2.4% | $49.95M-1.9% | $50.9M-7.8% | ||
| $8.29M+1.5% | $8.17M-11.9% | $9.27M-10.1% | $10.32M+2,322% | $426K+15.4% | ||
| $1M0.0% | $1M— | —— | —— | —— | ||
| $1M0.0% | $1M— | —— | —— | —— | ||
| $88.07M-20.8% | $111.16M+27.4% | $87.27M— | —— | —— | ||
| $46.78M-3.4% | $48.44M-5.9% | $51.49M-1.3% | $52.17M-1.0% | $52.72M-9.5% | ||
| $18K+5.9% | $17K+6.3% | $16K+14.3% | $14K0.0% | $14K+7.7% | ||
| $30.61M-3.8% | $31.83M+0.5% | $31.67M-8.7% | $34.7M+8.6% | $31.96M-1.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Iovance Biotherapeutics, Inc.'s total assets?
- Iovance Biotherapeutics, Inc. (IOVA) holds $925.7M in total assets, down 4.3% year over year.
- How much debt does Iovance Biotherapeutics, Inc. have?
- Iovance Biotherapeutics, Inc. carries $46.8M in total debt against $721.8M of shareholders' equity, a debt-to-equity ratio of 0.06.
- How much cash does Iovance Biotherapeutics, Inc. have?
- Iovance Biotherapeutics, Inc. holds $196.5M in cash and equivalents.
- Can Iovance Biotherapeutics, Inc. cover its short-term obligations?
- Its current ratio is 3.60 — current assets exceed current liabilities.
- Where does Iovance Biotherapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
